Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

WHO reveals growing global cancer burden in line with World Cancer Day

The three most commonly occurring cancers in 2022 were lung, breast and colorectal cancer

- PMLiVE

How does funding flow in NHSE Regions? – Live Webinar

On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...

Petauri Evidence

- PMLiVE

Patient Recruitment & Retention Strategies in the 2024 Clinical Trial Landscape

In the landscape of the clinical trial industry in 2024, persistent challenges persist in the realms of patient recruitment and retention.

- PMLiVE

Takeda gains rights to Protagonist’s blood disorder asset in deal worth over $300m

Rusfertide is currently being evaluated in a phase 3 clinical trial to treat polycythaemia vera

dengue fever mosquito

Positive efficacy results for R21/Matrix-M malaria vaccine published in The Lancet

R21 was added to the World Health Organization's list of prequalified vaccines in December

- PMLiVE

AstraZeneca shares positive phase 3 results for acoramidis in ATTR cardiomyopathy

Up to 500,000 people worldwide are affected by the rare and progressive condition

- PMLiVE

Clinigen’s NaviGATE programme reveals knowledge gaps in rare disease community

There are over 7,000 rare diseases that impact more than 300 million people globally

- PMLiVE

The four priorities shaping the future of R&D

Looking at what lies ahead for the life sciences, set against a backdrop of increasing digitalisation, climate change and emerging public health challenges

- PMLiVE

Advancing Patient-Centered Cancer Care Through Education to #CloseTheCareGap

One of the next frontiers in oncology isn’t being explored in a lab. Instead, it’s advancing in hospitals and private clinics around the world, thanks to the hard work of...

Medscape Education

- PMLiVE

GSK’s Omjjara approved by MHRA to treat myelofibrosis patients with anaemia

The rare blood cancer affects approximately one in every 500,000 people worldwide

- PMLiVE

AbbVie announces NICE recommendation for blood cancer therapy Tepkinly

Around 5,500 new cases of diffuse large B-cell lymphoma are diagnosed in the UK every year

- PMLiVE

Sobi receives NICE recommendation for Zynlonta in two non-Hodgkin lymphomas

Over 10,000 people are diagnosed with a type of non-Hodgkin lymphoma every year in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links